Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Mesna 600mg tablets
0801000T0AAADAD
|
Mesna (Cancer) | Mesna | Malignant Disease and Immunosuppression | No data available |
|
Mesterolone 25mg tablets
0604020F0AAAAAA
|
Mesterolone | Mesterolone | Endocrine System | No data available |
|
Mestinon 60mg/5ml syrup
1002010Q0BBAEBF
|
Mestinon | Pyridostigmine bromide | Musculoskeletal and Joint Diseases | No data available |
|
Mesuximide 300mg capsules
0408010K0AAAAAA
|
Mesuximide | Mesuximide | Central Nervous System | No data available |
|
Meta Healthcare low protein hazelnut spread
0913451M0BBAAAA
|
Meta Healthcare food replacer discontinued or OTC spreads | Food replacer discontinued or OTC spreads (0913451) | Nutrition and Blood | No data available |
|
Meta Healthcare low protein pizza crackers
0913451H0BEAAAC
|
Meta Healthcare food replacer discontinued or OTC savoury biscuits | Food replacer discontinued or OTC savoury biscuits (0913451) | Nutrition and Blood | No data available |
|
Meta Healthcare low protein salty sticks
0913451H0BEABAD
|
Meta Healthcare food replacer discontinued or OTC savoury biscuits | Food replacer discontinued or OTC savoury biscuits (0913451) | Nutrition and Blood | No data available |
|
Metabolic Mineral Mixture powder
090401000BBDCA0
|
Proprietary compound foods for special diets | Other food for special diet preparations | Nutrition and Blood | No data available |
|
Metalcaptase gastro-resistant 150mg tablets
1001030F0BDAAAM
|
Metalcaptase | Penicillamine | Musculoskeletal and Joint Diseases | No data available |
|
Metalcaptase gastro-resistant 300mg tablets
1001030F0BDABAN
|
Metalcaptase | Penicillamine | Musculoskeletal and Joint Diseases | No data available |
|
Metalite 250mg capsules
0908010S0BBAAAD
|
Metalite | Trientine dihydrochloride | Nutrition and Blood | No data available |
|
Metalyse 10,000unit inj vials
0210020U0BBAAAA
|
Metalyse | Tenecteplase | Cardiovascular System | No data available |
|
Metalyse 5,000unit powder for solution for injection vials
0210020U0BBACAC
|
Metalyse | Tenecteplase | Cardiovascular System | No data available |
|
Metalyse 8,000unit inj vials
0210020U0BBABAB
|
Metalyse | Tenecteplase | Cardiovascular System | No data available |
|
Metanium Cradle Cap cream
1305020S0BHAADS
|
Metanium (Salicylic acid) | Salicylic acid | Skin | No data available |
|
Metaperex 400unit capsules
0906050P0DCAAAF
|
Metaperex | Vitamin E | Nutrition and Blood | No data available |
|
Metaraminol 10mg/1ml solution for injection ampoules
0207020L0AAABAB
|
Metaraminol | Metaraminol | Cardiovascular System | No data available |
|
Metatone oral solution
090700000BMBAAA
|
Proprietary compound preparation BNF 0907000 | Other bitter and tonic preparations | Nutrition and Blood | No data available |
|
Meted shampoo
1309000R0BBAAAA
|
Meted | Sulfur | Skin | No data available |
|
Metenix 5mg tablets
0202010V0BBAAAA
|
Metenix | Metolazone | Cardiovascular System | No data available |
|
Metformin 250mg/5ml oral liquid
0601022B0AAAKAK
|
Metformin hydrochloride | Metformin hydrochloride | Endocrine System | No data available |
|
Metformin 425mg/5ml oral liquid
0601022B0AAALAL
|
Metformin hydrochloride | Metformin hydrochloride | Endocrine System | No data available |
|
Metformin 5mg/5ml oral solution
0601022B0AAANAN
|
Metformin hydrochloride | Metformin hydrochloride | Endocrine System | No data available |
|
Metformin 850mg capsules
0601022B0AAAQAQ
|
Metformin hydrochloride | Metformin hydrochloride | Endocrine System | No data available |
|
Methadone 1.67mg/5ml oral liquid
0410030C0AAATAT
|
Methadone hydrochloride (Drug Dependence) | Methadone hydrochloride | Central Nervous System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.